Palmitoleic Acid Protects against Hypertension by Inhibiting NF‐κB‐Mediated Inflammation

• Published in: Molecular nutrition & food research Vol. 65; no. 12; pp. e2001025 - n/a
• Main Authors: Tang, Jun, Yang, Bo, Yan, Yinkun, Tong, Wenfeng, Zhou, Renke, Zhang, Junhui, Mi, Jie, Li, Duo
• Format: Journal Article
• Language: English
• Published: Germany Wiley Subscription Services, Inc 01.06.2021
• Subjects: Adolescent; Animals; Antihypertensive Agents - pharmacology; Aorta; Aorta - drug effects; Aorta - metabolism; Aorta - physiopathology; aortic remodeling; Beijing - epidemiology; Blood pressure; Blood Pressure - drug effects; Case-Control Studies; Child; Children; Cytokines; Epidemiology; Erythrocytes; Erythrocytes - metabolism; Fatty Acids, Monounsaturated - blood; Fatty Acids, Monounsaturated - pharmacology; Female; Humans; Hypertension; Hypertension - blood; Hypertension - drug therapy; Hypertension - epidemiology; Inflammation; Inflammation - drug therapy; Inflammation - metabolism; Male; NF-kappa B - metabolism; NF‐κB; Olive oil; Omega‐7 palmitoleic acid; Palmitoleic acid; Phospholipids; Rats; Rats, Inbred SHR; Regression models; Supplements; Ventricular Remodeling - drug effects; Beijing; NF-κB; blood pressure; aortic remodeling; Omega-7 palmitoleic acid; hypertension
• ISSN: 1613-4125; 1613-4133
• DOI: 10.1002/mnfr.202001025

Scope The role of palmitoleic acid (POA) in hypertension or blood pressure remains uncertain. This study aims to investigate the epidemiological association between circulating POA and primary hypertension in humans, and subsequently evaluate the effects of exogenous POA on blood pressure and aortic remodeling in spontaneously hypertensive rats (SHRs). Methods and results A case‐control study of 349 hypertensive and 1396 normotensive children and adolescents is conducted, and found hypertensive cases show significant lower erythrocyte phospholipid POA than normotensive controls (p < 0.001). In conditional logistic regression model, participants in the top quartile of POA have a lower prevalence of primary hypertension than those in the bottom (multivariate‐adjusted OR: 0.47, 95% CI: 0.25–0.89). In animal study, 24 SHRs are randomly assigned to n‐3 PUFAs (500 mg kg‐1), POA (500 mg kg‐1), or vehicle (olive oil) for 8 weeks. At the end of intervention, as compared to SHRs treated with vehicle, SHRs treated with POA shows significantly decreased systolic blood pressure (SBP), improved aortic remodeling, and also decreased aortic expressions of NF‐κB and its downstream proinflammatory cytokines. Conclusions Circulating POA is inversely associated with risk of primary hypertension, and exogenous POA supplementation can decrease SBP and improve aortic remodeling by inhibiting NF‐κB‐mediated inflammation. The role of palmitoleic acid (POA) in hypertension remains unknown and even controversial. We found that circulating POA is inversely associated with risk of primary hypertension, and exogenous POA supplementation decreased systolic blood pressure (SBP) and improved aortic remodeling in spontaneously hypertensive rats (SHRs) by inhibiting NF‐κB mediated inflammation. Collectively,our study supports a beneficial role of POA in hypertension.